Cabernet Pharmaceuticals and Lilly Form Pharmacogenetics Alliance to Help Deliver Tailored Therapeutics to Patients

DURHAM, N.C. & INDIANAPOLIS--()--Cabernet Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE:LLY) today announced an alliance to further integrate pharmacogenetics into Lillys drug-development efforts.

Pharmacogenetics, the study of the genetic basis for varying individual response to medicines, helps to identify patient populations most likely to benefit from specific medicines and, just as importantly, those patients least likely to respond. Pharmacogenetic research also helps to define which patient groups are more likely or less likely to experience side effects.

Under the agreement, Cabernet consultants will join clinical-development teams at Lilly to assist in applying pharmacogenetics to selected development projects. Financial terms were not disclosed.

Pharmacogenetics has come of age, said Stephen Eck, vice president, Translational Medicine and Pharmacogenomics, at Lilly. It is one of the tools we increasingly bring to developing tailored therapeutics for better-defined patient groups. The experience of Cabernet in applying pharmacogenetics to drug development will supplement Lillys in-house capabilities, providing us a flexible resource as we manage the dynamics of our R&D pipeline.

Allen D. Roses, M.D., president and chief executive officer of Cabernet, said: We are delighted to form an alliance with a company of Lillys stature, a company that is committed to developing medicines that can be used with greater precision. We look forward to working closely with Lillys R&D organization to further our common mission of delivering the right medicines at the right doses to the right patients.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Cabernet Pharmaceuticals

Cabernet is a pharmacogenetics and project-management consultancy committed to helping its clients develop drugs with a greater chance of success. For more information, visit www.cabernetpharma.com.

Contacts

For Cabernet Pharmaceuticals, Inc.:
Richard Koenig at Biosyntax LLC
Office: 610-727-4505
Cell: 610-213-0725
or
For Eli Lilly and Company:
Christine Van Marter
Office: 317-651-1473

Contacts

For Cabernet Pharmaceuticals, Inc.:
Richard Koenig at Biosyntax LLC
Office: 610-727-4505
Cell: 610-213-0725
or
For Eli Lilly and Company:
Christine Van Marter
Office: 317-651-1473